^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Ruxience (rituximab-pvvr) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/01/2020
Excerpt:
Ruxience is indicated for the treatment of previously untreated patients with stage III‑IV follicular lymphoma in combination with chemotherapy.
Secondary therapy:
Chemotherapy
